If you made any changes in Pure, your changes will be visible here soon.

Research Output 1982 2019

Filter
Article
2019

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journalArticle

Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases
3 Citations (Scopus)

A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Mayer, I. A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M., Fasching, P. A., Colleoni, M., Wolff, A. C., Winer, E. P., Singer, C. F., Hurvitz, S., Estevez, L. G., Van Dam, P. A., Kummel, S., Mundhenke, C., Holmes, F., Babbar, N., Charbonnier, L., Diaz-Padilla, I. & 3 others, Vogl, F. D., Sellami, D. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 10, p. 2975-2987 13 p.

Research output: Contribution to journalArticle

Open Access
letrozole
Hormones
Breast Neoplasms
Placebos
Exanthema
3 Citations (Scopus)

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer

Croessmann, S., Formisano, L., Kinch, L. N., Gonzalez-Ericsson, P. I., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E. H., Cristofanilli, M., He, J., Cutler, R. E., Lalani, A. S., Miller, V. A., Lanman, R. B., Grishin, N. V. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 277-289 13 p.

Research output: Contribution to journalArticle

Estradiol Congeners
Estrogen Receptors
Breast Neoplasms
Mutation
MCF-7 Cells

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. L. & Neven, P., Jan 1 2019, (Accepted/In press) In : Clinical Drug Investigation.

Research output: Contribution to journalArticle

Consultants
Breast Neoplasms
Pharmaceutical Preparations
fulvestrant
1 Citation (Scopus)

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K. M., Koss, B., Budhraja, A. & 7 others, Opferman, J. T., Kim, K., Arteaga, C. L., Moore, W. J., Olejniczak, E. T., Savona, M. R. & Fesik, S. W., Apr 25 2019, In : Journal of Medicinal Chemistry. 62, 8, p. 3971-3988 18 p.

Research output: Contribution to journalArticle

Myeloid Leukemia
Myeloid Cells
Heterografts
Neoplasms
Triple Negative Breast Neoplasms
1 Citation (Scopus)
1-Phosphatidylinositol 4-Kinase
Biomarkers
Hormones
Breast Neoplasms
Growth
2 Citations (Scopus)

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ERþ/HER2þ breast cancers: Implications to the EXTENET trial

Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S., Gonzalez Ericsson, P. I., Sanders, M., Balko, J. M., Avogadri-Connors, F., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & Arteaga, C. L., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 771-783 13 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Cyclin D1
Gene Expression
fulvestrant
2018
5 Citations (Scopus)

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Campone, M., Im, S. A., Iwata, H., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Cortés, J., De Laurentiis, M., Arteaga, C. L., Jiang, Z., Jonat, W., Le Mouhaër, S., Sankaran, B., Bourdeau, L. & 3 others, El-Hashimy, M., Sellami, D. & Baselga, J., Nov 1 2018, In : European Journal of Cancer. 103, p. 147-154 8 p.

Research output: Contribution to journalArticle

Placebos
Phosphatidylinositol 3-Kinase
Hormones
Breast Neoplasms
Survival
5 Citations (Scopus)

ERþ Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J., Alejandro, J. P. F., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Jun 1 2018, In : Clinical Cancer Research. 24, 11, p. 2517-2529 13 p.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Neoplasms
Genes
97 Citations (Scopus)

HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Duygu Selcuklu, S., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 8 2018, In : Nature. 554, 7691, p. 189-194 6 p.

Research output: Contribution to journalArticle

Phosphotransferases
Mutation
Neoplasms
Biliary Tract Neoplasms
Missense Mutation
1 Citation (Scopus)

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Luo, N., Formisano, L., Gonzalez-Ericsson, P. I., Sanchez, V., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B. & Balko, J. M., Mar 5 2018, (Accepted/In press) In : OncoImmunology.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Cell Death
Ligands
Programmed Cell Death 1 Receptor
1 Citation (Scopus)

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program

Pulley, J. M., Jerome, R. N., Ogletree, M. L., Bernard, G. R., Lavieri, R. R., Zaleski, N. M., Hong, C. C., Shirey-Rice, J. K., Arteaga, C. L., Mayer, I. A., Holroyd, K. J. & Cook, R. S., Feb 1 2018, In : Targeted Oncology. 13, 1, p. 61-68 8 p.

Research output: Contribution to journalArticle

Neoplasm Metastasis
Neoplasms
Circulating Neoplastic Cells
Single Nucleotide Polymorphism
Therapeutics
1 Citation (Scopus)

Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Unni, N., Sudhan, D. R. & Arteaga, C. L., Aug 1 2018, In : Clinical Cancer Research. 24, 15, p. 3483-3485 3 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Estrogen Receptors
Disease-Free Survival
Placebos
Neoplasms
4 Citations (Scopus)

PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Mar 15 2018, In : Clinical Cancer Research. 24, 6, p. 1426-1435 10 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Oncogenes
Phenotype
S 6
Structural Models
4 Citations (Scopus)

TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association

Zonneville, J., Safina, A., Truskinovsky, A. M., Arteaga, C. L. & Bakin, A. V., Jun 19 2018, In : BMC Cancer. 18, 1, 670.

Research output: Contribution to journalArticle

Pericytes
Endothelium
Neoplasms
Fibronectins
Fibroblasts

The attenuation distribution across the long axis of breast cancer liver metastases at CT: A quantitative biomarker for predicting overall survival

Abramson, R. G., Lakomkin, N., Hainline, A., Kang, H., Hutson, M. S. & Arteaga, C. L., Jan 1 2018, In : American Journal of Roentgenology. 210, 1, p. W1-W7

Research output: Contribution to journalArticle

Liver Neoplasms
Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Survival
2 Citations (Scopus)

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. & Neven, P., Nov 1 2018, In : Clinical Drug Investigation. 38, 11, p. 1071-1075 5 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Mutation
Neoplasm Genes
Therapeutics
fulvestrant
50 Citations (Scopus)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C. & 1 others, O'Shaughnessy, J., Jul 1 2018, In : Annals of Oncology. 29, 7, p. 1541-1547 7 p.

Research output: Contribution to journalArticle

letrozole
Placebos
Hormones
Breast Neoplasms
Confidence Intervals
2017
15 Citations (Scopus)

18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials

Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Jun 15 2017, In : Clinical Cancer Research. 23, 12, p. 3053-3060 8 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Biomarkers
Pharmaceutical Preparations
Down-Regulation
Tamoxifen
29 Citations (Scopus)

An acquired HER2T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R., Lanman, R., Berger, M. F., Hyman, D. M., Solit, D. B., He, J., Miller, V., Cutler, R. E., Lalani, A. S., Cross, D., Lovly, C. M., Meiler, J. & Arteaga, C. L., Jan 1 2017, In : Cancer Discovery. 7, 6, p. 575-585 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Mutation
Plasmacytoma
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
Isoleucine
6 Citations (Scopus)

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Gonzalez Ericsson, P. I., Sanders, M. E., Dugger, T. C., Formisano, L., Guerrero-Zotano, A., Red-Brewer, M., Young, C. D., Lantto, J., Pedersen, M. W., Kragh, M., Horak, I. D. & Arteaga, C. L., Nov 1 2017, In : Journal of the National Cancer Institute. 109, 11

Research output: Contribution to journalArticle

Neutralizing Antibodies
Neuregulin-1
Breast Neoplasms
Ligands
Pharmaceutical Preparations
92 Citations (Scopus)

A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., Li, Y., Cantley, L. C., Winer, E. & Arteaga, C. L., Jan 1 2017, In : Clinical Cancer Research. 23, 1, p. 26-34 9 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Neoplasms
Mutation
Maximum Tolerated Dose
22 Citations (Scopus)

A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67

Jovanovic, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., Johnson, K. C., Sanchez, V., Rosenbluth, J. M., Dillon, P. M., Forero-Torres, A., Chang, J. C., Meszoely, I. M., Grau, A. M., Lehmann, B. D., Shyr, Y. & 4 others, Sheng, Q., Chen, S. C., Arteaga, C. L. & Pietenpol, J. A., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4035-4045 11 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
DNA Damage
Mutation
Arm
Genes
19 Citations (Scopus)

Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Guerrero-Zotano, A. L., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T. P. & 1 others, Arteaga, C. L., Oct 15 2017, In : Clinical Cancer Research. 23, 20, p. 6138-6151 14 p.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Ligands
RNA Sequence Analysis
124 Citations (Scopus)

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, J., Im, S. A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Takahashi, M., Vuylsteke, P., Hachemi, S. & 5 others, Dharan, B., Di Tomaso, E., Urban, P., Massacesi, C. & Campone, M., Jul 1 2017, In : The Lancet Oncology. 18, 7, p. 904-916 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Placebos
Hormones
Breast Neoplasms
Disease-Free Survival
12 Citations (Scopus)

Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sanchez, V., Rexer, B. N., Sánders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Jun 15 2017, In : Cancer Research. 77, 12, p. 3280-3292 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Integrins
Extracellular Matrix
Collagen
Breast Neoplasms
8 Citations (Scopus)

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors

Polosukhina, D., Love, H. D., Correa, H., Su, Z., Dahlman, K. B., Pao, W., Moses, H. L., Arteaga, C. L., Lovvorn, H. N., Zent, R. & Clark, P. E., Apr 1 2017, In : Molecular Oncology. 11, 4, p. 405-421 17 p.

Research output: Contribution to journalArticle

Wilms Tumor
Phosphatidylinositol 3-Kinases
Catenins
Mutation
Disease Progression
16 Citations (Scopus)

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gómez, H., Rizzo, M., Toy, W. & 15 others, Chandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Aug 9 2017, In : Science Translational Medicine. 9, 402, aai7993.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Estrogen Receptor Modulators
Neoplasms
12 Citations (Scopus)

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4323-4334 12 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Drug Combinations
Heterografts
Trastuzumab
43 Citations (Scopus)

Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S. & Arteaga, C. L., May 1 2017, In : Cancer Research. 77, 9, p. 2488-2499 12 p.

Research output: Contribution to journalArticle

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
RNA Interference
Protein Kinases
Breast Neoplasms
45 Citations (Scopus)

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., Lee, T., Gómez, H., Lluch, A., Pérez-Fidalgo, J. A., Wolf, M. M., Andrejeva, G., Rathmell, J. C., Fesik, S. W. & Arteaga, C. L., Oct 3 2017, In : Cell Metabolism. 26, 4, p. 633-647.e7

Research output: Contribution to journalArticle

Neoplastic Stem Cells
Oxidative Phosphorylation
Triple Negative Breast Neoplasms
Breast Neoplasms
Drug Therapy
6 Citations (Scopus)

Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors

Abramson, V. G., Supko, J. G., Ballinger, T., Cleary, J. M., Hilton, J. F., Tolaney, S. M., Chau, N. G., Cho, D. C., Pearlberg, J., Lager, J., Shapiro, G. I. & Arteaga, C. L., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3520-3528 9 p.

Research output: Contribution to journalArticle

Neutralizing Antibodies
Phosphatidylinositol 3-Kinases
Pharmacokinetics
Safety
Neoplasms
20 Citations (Scopus)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

O’Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., Hart, L. L., Villanueva, C., Jakobsen, E., Beck, J. T., Lindquist, D., Souami, F., Mondal, S., Germa, C. & Hortobagyi, G. N., Nov 21 2017, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-8 8 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Disease-Free Survival
Placebos
Safety
26 Citations (Scopus)

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., Bezwada, D., Patel, B., Song, Y., Costa, C., Naxerova, K., Wong, C. S. F., Kloepper, J., Das, R., Tam, A., Tanboon, J. & 13 others, Duda, D. G., Miller, R., Siegel, M. B., Anders, C. K., Sanders, M., Estrada, M. V., Schlege, R., Arteaga, C. L., Brachtel, E., Huang, A., Fukumura, D., Engelman, J. A. & Jain, R. K., May 24 2017, In : Science Translational Medicine. 9, 391

Research output: Contribution to journalArticle

Phosphotransferases
Breast Neoplasms
Neoplasm Metastasis
Brain
Brain Neoplasms
5 Citations (Scopus)

Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors

Limoge, M., Safina, A., Truskinovsky, A. M., Aljahdali, I., Zonneville, J., Gruevski, A., Arteaga, C. L. & Bakin, A. V., Sep 1 2017, In : Oncotarget. 8, 37, p. 61969-61981 13 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Growth
Neoplasms
Angiogenesis Inducing Agents
Mitogen-Activated Protein Kinase 14
2016
26 Citations (Scopus)

Drug response in organoids generated from frozen primary tumor tissues

Walsh, A. J., Cook, R. S., Sanders, M. E., Arteaga, C. L. & Skala, M. C., Jan 7 2016, In : Scientific Reports. 6, 18889.

Research output: Contribution to journalArticle

Organoids
Pharmaceutical Preparations
Neoplasms
Dimethyl Sulfoxide
Freezing
12 Citations (Scopus)

Is there a future for AKT inhibitors in the treatment of cancer?

Jansen, V. M., Mayer, I. A. & Arteaga, C. L., Jun 1 2016, In : Clinical Cancer Research. 22, 11, p. 2599-2601 3 p.

Research output: Contribution to journalArticle

Estrogen Receptor Modulators
Phosphatidylinositol 3-Kinases
Neoplasms
Breast Neoplasms
Therapeutics
61 Citations (Scopus)

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Guerrero-Zotano, A., Mayer, I. A. & Arteaga, C. L., Dec 1 2016, In : Cancer and Metastasis Reviews. 35, 4, p. 515-524 10 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Drug Resistance
Breast Neoplasms
Neoplasms
Therapeutics
9 Citations (Scopus)

PIK3CAH1047R - And Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Cheng, H., Liu, P., Ohlson, C., Xu, E., Symonds, L., Isabella, A., Muller, W. J., Lin, N. U., Krop, I. E., Roberts, T. M., Winer, E. P., Arteaga, C. L. & Zhao, J. J., Jun 9 2016, In : Oncogene. 35, 23, p. 2961-2970 10 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Tumor Escape
Mitogen-Activated Protein Kinase Kinases
Breast Neoplasms
Mutation
124 Citations (Scopus)

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sánchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Doimi, F. D. & 5 others, Gómez, H., Ryzhov, S. V., Darcy, P. K., Arteaga, C. L. & Balko, J. M., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1499-1509 11 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Mitogen-Activated Protein Kinase Kinases
Breast Neoplasms
Immune Evasion
455 Citations (Scopus)

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., Andre, F., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan, A., Jakobsen, E. & 17 others, Nusch, A., Burdaeva, O., Grischke, E. M., Alba, E., Wist, E., Marschner, N., Favret, A. M., Yardley, D., Bachelot, T., Tseng, L. M., Blau, S., Xuan, F., Souami, F., Miller, M., Germa, C., Hirawat, S. & O'Shaughnessy, J., Nov 3 2016, In : New England Journal of Medicine. 375, 18, p. 1738-1748 11 p.

Research output: Contribution to journalArticle

letrozole
Hormones
Breast Neoplasms
Placebos
Disease-Free Survival
25 Citations (Scopus)

Systematic prioritization of druggable mutations in ~5000 genomes across 16 cancer types using a structural genomics-based approachS

Zhao, J., Cheng, F., Wang, Y., Arteaga, C. L. & Zhao, Z., Feb 1 2016, In : Molecular and Cellular Proteomics. 15, 2, p. 642-656 15 p.

Research output: Contribution to journalArticle

Genomics
Genes
Genome
Mutation
Neoplasms
232 Citations (Scopus)

The PI3K/AKT pathway as a target for cancer treatment

Mayer, I. A. & Arteaga, C. L., Jan 14 2016, In : Annual Review of Medicine. 67, p. 11-28 18 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Oncology
Phosphatidylinositols
Tumors
Phosphotransferases
30 Citations (Scopus)

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K. & 26 others, Moon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jul 13 2016, In : eLife. 5, 2016JULY, e15828.

Research output: Contribution to journalArticle

Estrogen Receptors
Tumors
Breast Neoplasms
Pharmacokinetics
Tamoxifen
3 Citations (Scopus)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

Cheng, F., Zhao, J., Hanker, A. B., Brewer, M. R., Arteaga, C. L. & Zhao, Z., Dec 1 2016, In : Breast Cancer Research and Treatment. 160, 3, p. 457-474 18 p.

Research output: Contribution to journalArticle

Proteome
Transcriptome
Estrogen Receptors
Breast Neoplasms
Neoplasms
37 Citations (Scopus)

Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population

Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R. & Arteaga, C. L., Jan 15 2016, In : Cancer Research. 76, 2, p. 440-452 13 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Population
32 Citations (Scopus)

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

Balko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltnane, J. M., Dávila-González, D., Wang, K., Sánchez, V., Dean, P. T., Combs, S. E., Hicks, D., Pinto, J. A., Landis, M. D., Doimi, F. D., Yelensky, R., Miller, V. A., Stephens, P. J., Rimm, D. L., Gómez, H., Chang, J. C. & 3 others, Sanders, M. E., Cook, R. S. & Arteaga, C. L., Apr 13 2016, In : Science Translational Medicine. 8, 334, 334ra53.

Research output: Contribution to journalArticle

Janus Kinase 2
Triple Negative Breast Neoplasms
Neoplasms
Drug Therapy
Breast Neoplasms
2015
17 Citations (Scopus)

Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer

Young, C. D., Zimmerman, L. J., Hoshino, D., Formisano, L., Hanker, A. B., Gatza, M. L., Morrison, M. M., Moore, P. D., Whitwell, C. A., Dave, B., Stricker, T., Bhola, N. E., Silva, G. O., Patel, P., Brantley-Sieders, D. M., Levin, M., Horiates, M., Palma, N. A., Wang, K., Stephens, P. J. & 8 others, Perou, C. M., Weaver, A. M., O'Shaughnessy, J. A., Chang, J. C., Park, B. H., Liebler, D. C., Cook, R. S. & Arteaga, C. L., Jan 1 2015, In : Molecular and Cellular Proteomics. 14, 7, p. 1959-1976 18 p.

Research output: Contribution to journalArticle

Paracrine Communication
Extracellular Signal-Regulated MAP Kinases
Epidermal Growth Factor Receptor
Breast Neoplasms
Mutation
16 Citations (Scopus)

Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts

Walsh, A. J., Cook, R. S., Lee, J. H., Arteaga, C. L. & Skala, M. C., Feb 1 2015, In : Journal of Biomedical Optics. 20, 2, 026004.

Research output: Contribution to journalArticle

collagens
Heterografts
Collagen
breast
Tumors
10 Citations (Scopus)

Cytokeratin19 induced by HER2ERK binds and stabilizes HER2 on cell membranes

Ju, J. H., Oh, S., Lee, K. M., Yang, W., Nam, K. S., Moon, H. G., Noh, D. Y., Kim, C. G., Park, G., Park, J. B., Lee, T., Arteaga, C. L. & Shin, I., Apr 4 2015, In : Cell Death and Differentiation. 22, 4, p. 665-676 12 p.

Research output: Contribution to journalArticle

Ubiquitination
Proteasome Endopeptidase Complex
Proteomics
Small Interfering RNA
Cell Survival